Genome Editing of Veterinary Relevant Mycoplasmas Using a CRISPR-Cas Base Editor System

Thomas Ipoutcha1, Fabien Rideau1, Geraldine Gourgues1

  • 1Univ. Bordeaux, INRAE, UMR BFP, Villenave d'Ornon, France.

Insights

Researchers adapted a CRISPR-Cas9 base editor for mycoplasmas, enabling targeted mutations in key animal pathogens like Mycoplasma gallisepticum and Mycoplasma bovis. This tool facilitates studying virulence factors and developing better vaccines.

Area of Science:

  • Microbiology
  • Bacterial Pathogenesis
  • Genetic Engineering

Background:

  • Mycoplasmas are minimal bacteria causing chronic inflammatory diseases in humans and livestock.
  • Limited genetic tools hinder the study of mycoplasma virulence factors and vaccine development.
  • Understanding mycoplasma pathogenicity is crucial for animal and human health.

Purpose of the Study:

  • To adapt an efficient Cas9-Base Editor system for targeted gene editing in pathogenic mycoplasmas.
  • To demonstrate the system's efficacy in disrupting virulence factors in key species.
  • To provide a novel genetic tool for studying mycoplasma pathogenicity.

Main Methods:

  • Adaptation of an inducible SpdCas9-pmcDA1 cytosine deaminase system.
  • Targeted disruption of virulence factors in Mycoplasma gallisepticum, Mycoplasma bovis, and Mycoplasma mycoides subsp. mycoides.
  • Optimization of induction times and concentrations for editing efficiency.
  • Whole-genome sequencing to assess off-target mutations.

Main Results:

  • Successful targeted mutations introduced into three major pathogenic mycoplasma species.
  • Disruption of multiple virulence factors, including 54 insertion sequence transposases in one experiment.
  • Limited off-target mutations observed, indicating system specificity.
  • Demonstrated efficiency, speed, and ease of use of the developed genetic tool.

Conclusions:

  • The adapted Cas9-Base Editor system is a powerful and versatile tool for genetic manipulation of pathogenic mycoplasmas.
  • This tool will significantly advance research into mycoplasma virulence and pathogenicity.
  • Facilitates the development of improved vaccines and therapeutic strategies against mycoplasma infections.

Related Concept Videos

CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
180
CRISPR01:59

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
52.8K
CRISPR and crRNAs02:53

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.3K